So it seems like the injectable vaccine will be strictly preferable if the nOPV strategy fails. It's only disadvantage is that it does not prevent the recipient from spreading polio to others if they become infected, and it looks like that disadvantage may have been illusory anyway.
It's also worth paying attention to the precise distinction between vaccine-derived poliovirus, which is the problem this article was about, and VAPP. VDPD is basically equivalent to normal wild-type poliovirus in terms of its infectivity and effects, but only happens once the vaccine poliovirus has been circulating and mutating for a while and can be protected against via vaccination. VAPP is caused by vaccination and can affect the recipients or those around them, but unlike VDPD the people who suffer from it shouldn't pose any more danger to others than any other vaccine receipient.
That seems like it would make the oral vaccine even worse, compared to the injected vaccine. Again, I'm not sure why they think reintroducing traditional type-2 OPV is a good idea if the injected form that won't cause vaccine-derived outbreaks is so easily available. (Of course nOPV is expected to be better than the former OPV, but it's yet to be available.)
I'm not exactly sure why the WHO rushed to pull type 2 from the oral vaccine before there was sufficient supply of the inactivated vaccine to replace it, but I get the impression that they didn't expect it would be necessary because they thought that type 2 virus would rapidly disappear once they did so.
http://polioeradication.org/wp-content/uploads/2016/07/sop-p...